Switch to
More onapp

Zydus Lifesciences Ltd

ZYDUSLIFE
Health CarePharmaceuticals
MidcapWith a market cap of ₹41,434 cr, stock is ranked 120
Low RiskStock is 1.54x as volatile as Nifty
419.9010.55 (+2.58%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
MidcapWith a market cap of ₹41,434 cr, stock is ranked 120
Low RiskStock is 1.54x as volatile as Nifty

Key MetricsEdit

PE RatioPE Ratio
9.23
PB RatioPB Ratio
2.17
Dividend YieldDiv. Yield
0.62%
Sector PESector PE
35.47
Sector PBSector PB
4.33
Sector Div YldSctr Div Yld
0.91%

Forecast & RatingsDetailed Forecast 

50%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Zydus Lifesciences Ltd is an India-based life sciences company. The Company has a pipeline for Biologics and Vaccines.

Brands

Cadila

Pharmaceutical company

Zydus Cadila

Investor PresentationView older 

Aug 10, 2022

PDF
View Older Presentations

Brands

Cadila

Pharmaceutical company

Zydus Cadila

Financial TrendFinancial statements 

201920202021202213.3714.3714.4517.851.851.182.134.49
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Press Release 
Announced OnOct 3, 2022

Zydus Lifesciences Limited has informed the Exchange about press release dated 03-Oct-2022 titled Zydus receives final approval from USFDA and 180 days shared exclusivity for Mirabegron Extended-Release Tablets 3.10.22 | Download

Zydus Lifesciences Limited has informed the Exchange about press release dated 03-Oct-2022 titled Zydus receives final approval from USFDA and 180 days shared exclusivity for Mirabegron Extended-Release Tablets 3.10.22 | Download

Press Release 
Announced OnOct 1, 2022

Zydus Lifesciences Limited has informed the Exchange about press release dated 01-Oct-2022 titled Zydus receives final approval from the USFDA for Sildenafil for Oral Suspension | Download

Zydus Lifesciences Limited has informed the Exchange about press release dated 01-Oct-2022 titled Zydus receives final approval from the USFDA for Sildenafil for Oral Suspension | Download

Cash Dividend 
Ex. DateJul 28, 2022

Final • Div/Share: ₹ 2.5

See all events